When looking for undervalued stocks in cannabis, US’s Real Brands Inc. jumps out based on its current selling price. Selling for $0.13 USD and down almost 5% on the day, RLBD stock is intriguing for its bright future ahead.
Undervalued Stocks in Cannabis
The cannabis sector is currently going through a market correction. This translates as red stocks across the board. News doesn’t even seem to be impacting prices; many companies are announcing impressive things, but it doesn’t matter. The entire market seems to be pulling back after September’s surge in the run-up to adult-use cannabis legalization in Canada.
As a result of the downturn, some companies may be oversold and are presently showing undervalued stocks. One such company is Real Brands Inc., a penny stock that has massive potential ahead and a very low price-tag.
About Real Brands Inc. (OTC:RLBD)
Florida’s Real Brands lies relatively under the radar, thus its potential as an undervalued stock. With a market cap of $16.4 million USD, the company specializes in brand development and has strong ties to the drinks industry. However, it has recently moved into the cannabis sector with an LOI to acquire Humboldt Brands and Hemp-Aid.
>> Cannabis Penny Stocks: US Hemp-CBD Producers to Watch!
The company has the CBD market in its sights and is on a path to expand its brand holdings while “creating unique marketing strategies in at least three CBD Categories: smokables, edibles and topical balms and lotions.”
Already on the books is CBD Pharmacy—a CBD cartridge brand that sold out its initial release and looks set to do the same for its next distribution.
RLBD’s CEO Jerry Pearring said the following about the proposed acquisitions:
“The proposed acquisition of the Humboldt Brands and HempAid. trademarks represent the next step in Real Brand’s branding strategy. We are pleased with the development to date of the CBD Pharmacy brand launched in 2017 and believe these trademarks will fast-track our market segmented branding strategy.”
So are these undervalued stocks? Well, its hard to tell from the company’s past performance, but if we are to bank on its move into the CBD sector, $0.13 gets you a lot of bang for your buck.
Featured Image: Depositphotos/© ijeab